Sidoti Csr Weighs in on Assertio’s Q3 Earnings (NASDAQ:ASRT)

Assertio Holdings, Inc. (NASDAQ:ASRT) – Equities researchers at Sidoti Csr reduced their Q3 2025 earnings per share (EPS) estimates for shares of Assertio in a note issued to investors on Thursday, March 13th. Sidoti Csr analyst J. Sidoti now expects that the company will earn $0.00 per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share. Sidoti Csr also issued estimates for Assertio’s Q4 2025 earnings at $0.00 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Assertio in a report on Monday, December 16th.

Assertio Trading Up 0.2 %

NASDAQ:ASRT opened at $0.72 on Monday. Assertio has a 12-month low of $0.68 and a 12-month high of $1.80. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57. The business has a 50 day simple moving average of $0.81 and a 200 day simple moving average of $0.96. The firm has a market capitalization of $68.96 million, a P/E ratio of -0.99, a P/E/G ratio of 3.25 and a beta of 0.81.

Hedge Funds Weigh In On Assertio

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Thurston Springer Miller Herd & Titak Inc. raised its stake in Assertio by 33.7% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 67,500 shares of the company’s stock valued at $59,000 after acquiring an additional 17,000 shares in the last quarter. Palumbo Wealth Management LLC increased its holdings in shares of Assertio by 10.6% during the fourth quarter. Palumbo Wealth Management LLC now owns 205,598 shares of the company’s stock valued at $179,000 after purchasing an additional 19,637 shares during the period. Geode Capital Management LLC raised its stake in shares of Assertio by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 1,095,911 shares of the company’s stock valued at $955,000 after purchasing an additional 21,059 shares in the last quarter. Empowered Funds LLC lifted its holdings in Assertio by 5.4% in the third quarter. Empowered Funds LLC now owns 431,913 shares of the company’s stock worth $510,000 after purchasing an additional 21,976 shares during the period. Finally, Captrust Financial Advisors bought a new position in Assertio in the 3rd quarter valued at about $26,000. 48.96% of the stock is currently owned by institutional investors and hedge funds.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.